Clinical Trial Detail

NCT ID NCT02560012
Title Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements no
Sponsors The University of Texas Health Science Center, Houston
Indications

renal cell carcinoma

Therapies

Everolimus

Sorafenib

Temsirolimus

Axitinib

Sunitinib

Pazopanib

Age Groups: adult

No variant requirements are available.